4-氰基-2-氟苯硼酸频那醇酯 | 1035235-29-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氰基-2-氟苯硼酸频那醇酯
• 中文别名: 4-氰基-2-氟苯基硼酸频哪醇酯；2-氟-4-氰基苯硼酸频哪醇酯
• 英文名称: 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile
• 英文别名: 2-fluoro-4-cyanophenylboronic acid pinacol ester
• CAS: 1035235-29-0
• 化学式: C₁₃H₁₅BFNO₂
• mdl: MFCD09998162
• 分子量: 247.077
• InChiKey: FEUINZSEHIJUBU-UHFFFAOYSA-N

物化性质

• 熔点：
  68-70°
• 沸点：
  342.9±32.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.85
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Cyano-2-fluorophenylboronic acid, pinacol ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
Avoid breathing dust/fume/gas/mist/vapours/spray
P261:
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Cyano-2-fluorophenylboronic acid, pinacol ester
CAS number: 1035235-29-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C13H15BFNO2
Molecular weight: 247.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氰基-2-氟苯硼酸频那醇酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 盐酸 、 potassium carbonate 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 21.0h， 生成 1-methylcyclopropyl (1R,5S,9r)-9-((7-(4-cyano-2-fluorophenyl)thieno[3,2-d]pyrimidin-4-yl)oxy)-3-oxa-7-azabicyclo[3.3.1]nonane-7-carboxylate
  参考文献：
  名称：

  [EN] BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF
  [FR] DÉRIVÉS HÉTÉROCYCLES BICYCLIQUES ET PROCÉDÉS D'UTILISATION DE CEUX-CI

  摘要：

  结构式I的化合物：是GPR119激动剂，用于治疗、控制或预防对GPR119激动有响应的疾病，如代谢相关疾病，如1型糖尿病、2型糖尿病、葡萄糖耐量不足、胰岛素抵抗、高血糖、高脂血症、高三酰甘油血症、高胆固醇血症、血脂异常或X综合征。这些化合物还被报道为在哺乳动物中控制体重增加、控制食物摄入和诱导饱腹感方面有用。

  公开号：

  WO2011159657A1
• 作为产物：
  描述：

  4-溴-3-氟苯腈 、 联硼酸频那醇酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium acetate 作用下， 以 1,4-二氧六环 为溶剂， 以1 g的产率得到4-氰基-2-氟苯硼酸频那醇酯
  参考文献：
  名称：

  [EN] SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF
  [FR] COMPOSÉ CYCLOTHIAZOLE À SIX CHAÎNONS ET SON UTILISATION
  [ZH] 六元环并噻唑类化合物及其应用

  摘要：

  本公开提供了一种式（I）所示的六元环并噻唑类化合物或其药学上可接受的盐，含有它们的药物组合物以及它们在预防或治疗DNA聚合酶θ介导的疾病中的应用。

  公开号：

  WO2023134739A1

文献信息

• Certain pyrazoline derivatives with kinase inhibitory activity
  申请人：Adams Ruth S.

  公开号：US20080171754A1

  公开（公告）日：2008-07-17

  The present invention provides certain pyrazoline compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions and methods of using the compositions in the treatment of various diseases.

  本发明提供了某些吡唑啉化合物，可用作蛋白激酶的抑制剂。该发明还提供了药物组合物和使用这些组合物治疗各种疾病的方法。
• [EN] INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA PROTÉINE KINASE I INTERAGISSANT AVEC LE RÉCEPTEUR POUR LE TRAITEMENT D'UNE MALADIE
  申请人：UNIV TEXAS

  公开号：WO2021173917A1

  公开（公告）日：2021-09-02

  Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

  公开了抑制RIPK1的化合物，药物组合物以及治疗RIPK1介导的疾病的方法，如神经退行性疾病，炎症性疾病和癌症。
• [EN] ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS D'ARYL-PYRIDINE EN TANT QU'INHIBITEURS D'ALDOSTÉRONE SYNTHASE
  申请人：NOVARTIS AG

  公开号：WO2011061168A1

  公开（公告）日：2011-05-26

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5 and n are defined herein. The invention also relates to a method for manufacturing compounds of the invention, and their therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中R1、R2、R3、R4、R5和n在此处定义。该发明还涉及一种制造该发明化合物的方法，以及它们的治疗用途。本发明还提供了一种药理活性剂的组合和制药组合物。
• [EN] HEPATITIS B CORE PROTEIN MODULATORS<br/>[FR] MODULATEURS DES PROTÉINES DU NOYAU DE L'HÉPATITE B
  申请人：ASSEMBLY BIOSCIENCES INC

  公开号：WO2018053157A1

  公开（公告）日：2018-03-22

  The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound of formula:

  本公开提供了部分具有对乙型肝炎病毒Cp的变构效应物性的化合物。本文还提供了治疗病毒感染（如乙型肝炎）的方法，包括向需要的患者施用公开的化合物的公式：
• [EN] 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS<br/>[FR] INHIBITEURS 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DE PHD
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2014160810A1

  公开（公告）日：2014-10-02

  The present invention provides compounds of formula (I) which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.

  本发明提供了公式(I)的化合物，这些化合物可用作PHD的抑制剂，以及与HIF相关疾病的治疗方法，制备这些化合物及其中间体的药物组合物。